Melatonin alleviates neuroinflammation in ischemic stroke by regulating cGAS-mediated microglial pyroptosis signaling
- PMID: 40536992
- DOI: 10.4103/NRR.NRR-D-24-01070
Melatonin alleviates neuroinflammation in ischemic stroke by regulating cGAS-mediated microglial pyroptosis signaling
Abstract
Inflammation plays a key role in driving the secondary brain injury that follows ischemic stroke. Melatonin is an endogenous neuroendocrine hormone that regulates mitochondrial homeostasis. However, the role and mechanisms by which melatonin regulates microglial pyroptosis and the inflammatory cascade through double-stranded DNA (dsDNA)-sensing cyclic GMP-AMP synthase (cGAS) signaling warrant further study. Using middle cerebral artery occlusion mice, we investigated the effects of melatonin on cGAS-mediated pyroptosis and neuroinflammation. Middle cerebral artery occlusion model mice exhibited significantly increased DNA damage and cytoplasmic dsDNA release, as reflected by γH2AX staining, as well as heightened activation of the cytosolic dsDNA-sensing cGASSTING pathway, both of which were notably suppressed by melatonin treatment. Melatonin also mitigated NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome activation and nuclear factor (NF)-κB/gasdermin D-mediated pyroptosis in microglia following ischemic stroke, while exhibiting the capacity to attenuate the immune response to ischemia in mice. This led to reduced infiltration of peripheral neutrophils and monocytes/macrophages in the ischemic brain. Specifically, melatonin administration resulted in reductions in the numbers of ionized calcium-binding adapter molecule 1-positive cells and production of interleukin-6 and tumor necrosis factor-α by microglia. Regarding neurological outcomes, melatonin significantly reduced cerebral infarct volume and ameliorated neurological deficits in mice. Notably, the neuroprotective effect of melatonin was correlated with the inhibition of cGAS activity. We also developed and tested melatonin co-loaded macrophage membrane-biomimetic reactive oxygen species-responsive nanoparticles (Mϕ-MLT@FNGs), which exhibited therapeutic properties in middle cerebral artery occlusion mice. Our findings suggest that melatonin acts on microglial pyroptosis to inhibit neuroinflammation and reshape the immune microenvironment through regulation of the cGAS-STING-NF-κB signaling pathway. By doing so, melatonin rescues damaged brain tissue and protects neurological function, highlighting its potential as a neuroprotective treatment for ischemic stroke.
Keywords: STING; cGAS; immune injury; inflammation; ischemic stroke; melatonin; microglia; pyroptosis.
Copyright © 2025 Neural Regeneration Research.
Similar articles
-
Ursolic acid ameliorates cerebral ischemia-reperfusion injury by inhibiting NF-κB/NLRP3-mediated microglia pyroptosis and neuroinflammation.Front Pharmacol. 2025 Jul 11;16:1622131. doi: 10.3389/fphar.2025.1622131. eCollection 2025. Front Pharmacol. 2025. PMID: 40717974 Free PMC article.
-
Microglial STING activation promotes neuroinflammation and pathological changes in experimental mice with intracerebral haemorrhage.Acta Pharmacol Sin. 2025 Sep;46(9):2376-2392. doi: 10.1038/s41401-025-01540-8. Epub 2025 Apr 8. Acta Pharmacol Sin. 2025. PMID: 40200123
-
ALPK1 signaling pathway activation by HMGB1 drives microglial pyroptosis and ferroptosis and brain injury after acute ischemic stroke.Int Immunopharmacol. 2025 Mar 6;149:114229. doi: 10.1016/j.intimp.2025.114229. Epub 2025 Feb 10. Int Immunopharmacol. 2025. PMID: 39933362
-
New Insights on the Potential Role of Pyroptosis in Parkinson's Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics.Mol Neurobiol. 2025 Jul;62(7):9365-9384. doi: 10.1007/s12035-025-04818-4. Epub 2025 Mar 18. Mol Neurobiol. 2025. PMID: 40100493 Review.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials